Digital Course: Mechanistic Insights into Hepatotoxicity
CONFERENCE SERIES: Drug & Device Safety
Recorded at: World Pharma Congress
June 16, 2010
About this Product:
The course is designed for both pre-clinical and clinical scientists looking to better understand the mechanisms underlying drug-induced liver injury or DILI, and to help in the development of technologies and mechanism-based assays for early prediction of drug-induced hepatotoxicity.
Agenda At A Glance:
This course provides an overview of cellular pathways involved in:
- Mitochondrial dysfunction and Oxidative stress
- Excessive generation of reactive metabolites
- Inhibition of bile salt efflux protein and involvement of hepatic transporters in drug-induced hepatotoxicity
Amit S. Kalgutkar, Ph.D., Research Fellow, Pharmacokinetics, Dynamics and Metabolism Department, Pfizer Global R&D
Dr Kalgutkar received his B.Sc. (Chemistry) and M.Sc. (Organic Chemistry) degrees from the University of Bombay, India and a Ph.D. (Organic Chemistry) from Virginia Tech. He pursued post-doctoral studies in the laboratories of Prof. Lawrence Marnett at the department of biochemistry, Vanderbilt University prior to joining Pfizer in 1999. Dr. Kalgutkar is an accomplished scientific leader inside Pfizer as well as in the external scientific community with over 90 peer-reviewed papers, reviews and book chapters. He has been a member of the editorial board of Chemical Research in Toxicology (American Chemical Society publication). Dr. Kalgutkar is currently a Pfizer Research Fellow.
José E. Manautou, Ph.D., Associate Professor of Toxicology, Department of Pharmaceutical Sciences, University of Connecticut
Dr. José E. Manautou is Associate Professor of Toxicology and the Marlene L. Cohen and Jerome H. Fleisch Scholar in the Department of Pharmaceutical Sciences at the School of Pharmacy of the University of Connecticut. His research emphasizes mechanisms of toxicant action/interaction. His laboratory studies the role of multidrug resistance proteins in the hepatobiliary disposition of toxicants and the changes in expression of transport proteins in response to chemical liver injury. His group also investigates the biochemical and genetic determinants associated with the hepatoprotective actions of peroxisome proliferators and other chemicals that prevent drug liver injury. He has published numerous seminal articles on these research areas in both toxicology and liver-related journals. Dr. Manautou has been an active member of the Society of Toxicology (SOT) since he joined as a student member. In 2003, he was elected Councilor of the SOT and has also served in key committees and task forces for the society. Dr. Manautou was the recipient of the 2006 SOT Achievement Award and the 2008 AstraZeneca Traveling Lectureship Award. Dr. Manautou has served as member of the National Research Council Committee Assessing the Human Health Risks of Trichloroethylene and is currently Associate Editor for the journal Toxicology and Applied Pharmacology. He is also on the editorial board of four other journals. He served as member of the National Institutes of Health Xenobiotic and Nutrient Disposition and Action (XNDA) Study Section and as external reviewer of grants for the European Commission. Dr. Manautou was recently appointed the NIH College of CSR Reviewers and was just nominated to be a member of the NIEHS Board of Scientific Counselors. Dr. Manautou received his B.S. in Pharmacy from the University of Puerto Rico, Ph.D. in Pharmacology and Toxicology from Purdue University and postdoctoral training in biochemical toxicology at the University of Connecticut. He also conducted sabbatical research at the Amsterdam Liver Center of the University of Amsterdam, The Netherlands.
Yvonne Will, Ph.D., Associate Research Fellow, Compound Safety Prediction, Pfizer Global R&D
Dr Will has more than 10 years of expertise in studying mitochondrial function in disease and drug toxicity. She pursued her graduate studies at Oregon State University in the lab of Dr. Donald Reed where she focused on the relationships between glutathione deficiency and cellular and mitochondrial function/dysfunction. During her years at MitoKor, San Diego (2000-2003) she was involved in drug discovery aimed on improving mitochondrial function or preventing mitochondrial dysfunction in obesity, diabetes, and CNS related diseases. From 2003 until 2007, Dr. Will was a group leader in Drug Safety at Pfizer La Jolla, pioneering a screening paradigm for drug induced mitochondrial toxicity, supporting many therapeutic areas such as diabetes, obesity and antibiotics and anti-virals during that time she also held an adjunct faculty position at San Diego State University in the Toxicology program where she conducted lectures, taught laboratory courses and mentored MS students. In the fall of 2007, Dr. Will transferred to Pfizer Groton where she now leads a group of scientists in Compound Safety Prediction within Medicinal Chemistry. She continues to drive her belief in early safety screening using alternative models and state of the art technologies. Dr. Will recently published a book on drug induced mitochondrial toxicity together with Dr. James Dykens. Dr. Will has given many national and international lectures and seminars and continues to publish in peer reviewed journals.
About this Product:
Over 94 slides
Single Copy - $345.00
Site License - $1,380.00
About the Conference:
CHI’s World Pharmaceutical Congress encompasses a broad spectrum of topics that are very important to scientists in the pharmaceutical and biotechnology industry. This event focuses mainly on the pre-clinical aspects of drug discovery and development and consists of three separate Summits (Drug Safety Summit; Drug Discovery Innovation Summit; Screening and Imaging Summit) each featuring various tracks. The topics offer a broad-based perspective on what's going on in the field, tackling issues relevant to chemists, biologists, pharmacologists, toxicologists and clinicians alike. Each track features presentations, interactive panels and technology talks that cover the very latest on the topic, both on the scientific and the technical side. The World Pharmaceutical Congress also offers attendees and exhibitors ample opportunity to network, brain-storm and collaborate on various fronts.